Volume depletion

Papers on volume depletion

57 papers5 new in 30 days

Monday, November 2

Kidney Research and Clinical PracticeNov 2

Albuminuria as a treatment-response biomarker during layered kidney-protective therapy for albuminuric chronic kidney disease

ReviewAlbuminuria

Sunday, November 1

CureusNov 1

Lithium Toxicity Following Initiation of Semaglutide in a Patient With Bipolar Disorder: A Case Report

CT angiography of the head and neck.

Case reportLithium

Thursday, October 29

LifeOct 29

SGLT2 Inhibitors in Heart Failure and Comorbidities: Multidimensional Mechanisms and Clinical Evidence

ReviewSGLT2 inhibitors

Friday, October 23

Anesthesia and Pain MedicineOct 23

Whether to hold and what to measure: perioperative euglycemic ketoacidosis in patients taking SGLT2 inhibitors

ReviewSGLT2 inhibitors

Tuesday, October 20

Frontiers in EndocrinologyOct 20

Glucagon-like peptide-1 receptor agonists and aesthetic surgery: perioperative safety, timing, durability and body composition

Practical multidisciplinary algorithm for timing and perioperative planning in patients using GLP-1 receptor agonists who are seeking elective aesthetic surgery.

ReviewGLP-1 receptor agonists

Friday, October 2

MedicineOct 2

Renoprotective effects and safety of sodium-glucose cotransporter 2 inhibitors in diabetic chronic kidney disease: A systematic review and meta-analysis

Inclusion of literature quality assessment.

Meta-analysis of randomized trialsSGLT2 inhibitors

Aesthetic Surgery Journal Open ForumOct 2

Beyond Skin Laxity: GLP-1 Receptor Agonist-Induced Lean Mass Depletion and Surgical Tissue Quality in Aesthetic Surgery: A Narrative Review

ReviewGLP-1 receptor agonists

Monday, September 28

Diabetes, Obesity & MetabolismSep 28

GLP-1 drugs added to SGLT2 inhibitors linked to lower kidney risk

Adding a GLP-1 receptor agonist was linked to lower rates of major adverse kidney events (HR 0.70) compared with SGLT2 inhibitor monotherapy over 12 months.Adding a GLP-1 receptor agonist was linked to lower rates of major adverse kidney events (HR 0.70) compared with SGLT2 inhibitor monotherapy over 12 months.

Cohort study of 32,448 peopleKidney

Wednesday, September 16

American Journal of Cardiovascular DrugsSep 16

SGLT2 Inhibitors in Cardiovascular-Kidney-Metabolic Syndrome: Drugs Unifying Heart, Kidney, and Metabolism Pharmacotherapy

ReviewSGLT2 inhibitors

Tuesday, September 15

Frontiers in PharmacologySep 15

Effectiveness of SGLT2 inhibitors in slowing chronic kidney disease progression and reducing mortality: a meta-analysis

Flow chart showing the methodology of study selection.

Meta-analysis of randomized trialsSGLT2 inhibitors

Friday, September 11

CureusSep 11

Cardiorenal Protection in Type 2 Diabetes: A Systematic Review Comparing Glucagon-Like Peptide-1 Receptor Agonists and Sodium-Glucose Cotransporter-2 Inhibitors

PRISMA 2020 flow diagram of study identification, screening, eligibility, and inclusion.

Systematic review of studies in peopleSGLT2 inhibitors

Friday, September 4

Frontiers in Cardiovascular MedicineSep 4

Safety & efficacy of sodium glucose co-transport 2 (SGLT2) inhibitors in elderly patients with heart failure

Percentage of incidence of adverse events among elderly heart failure patients receiving SGLT2 inhibitors.

Cohort study of 126 peopleSGLT2 inhibitors

Wednesday, August 26

Science ProgressAug 26

Association of semaglutide use with kidney outcomes in adults with ADPKD: A propensity score-matched real-world study

Cohort study of 320 peopleSemaglutide

Friday, August 21

Journal of Diabetes InvestigationAug 21

Frailty and low body mass linked to stopping one diabetes drug class

Over 180 days, an estimated 9.1% of 616 Japanese adults aged 75 or older stopped sodium-glucose cotransporter 2 inhibitors because of drug-specific adverse events.Over 180 days, an estimated 9.1% of 616 Japanese adults aged 75 or older stopped sodium-glucose cotransporter 2 inhibitors because of drug-specific adverse events.

Cumulative incidence of SGLT2 inhibitor‐specific AE‐related discontinuation up to day 180 after SGLT2 inhibitor initiation.

Cohort · 616 peopleInterventions

Thursday, August 13

Diabetes, Obesity & MetabolismAug 13

SGLT2 Inhibitors and Outcomes in Elderly Patients With Chronic Kidney Disease: A Narrative Review

ReviewSGLT2 inhibitors

Handbook of Experimental PharmacologyAug 13

Safety and Tolerability of SGLT2 Inhibitors

ReviewInterventions

Monday, August 3

Drug Design, Development and TherapyAug 3

Adverse Events Associated with Incretin-Based Therapies: A Narrative Review on Mechanisms, Clinical Management, and Risk Mitigation

ReviewIncretin-based therapies

Saturday, August 1

High Blood Pressure & Cardiovascular PreventionAug 1

Efficacy and Safety of SGLT-2 Inhibitors in Patients with Uncontrolled or Resistant Hypertension: A Pilot Meta-Analysis of Randomized Clinical Trials

Meta-analysis of randomized trialsSGLT2 inhibitors

Friday, July 31

Hypertension ResearchJul 31

Early plasma volume and interstitial fluid responses to SGLT2 inhibitor, loop diuretics, and their combination in chronic kidney disease

Cohort study in peopleSGLT2 inhibitors

Saturday, July 11

MedicineJul 11

Frailty index and tolerability of SGLT2 inhibitors in elderly (≥75 years) patients with heart failure

Cohort study of 115 peopleSGLT2 inhibitors

Monday, June 29

Cardiovascular Diabetology Endocrinology ReportsJun 29

Safety of SGLT2 inhibitors versus DPP-4 inhibitors in super-elderly patients (≥ 80 years) with type 2 diabetes: a propensity score-matched cohort study

Cohort study of 65,119 peopleSGLT2 inhibitors

Saturday, June 6

ADA Scientific Sessions 2026 AbstractJun 6

Real-World Safety and Clinical Outcomes of SGLT2 Inhibitors in 195 Pediatric Patients

Cohort study of 195 peopleSGLT2 inhibitors

Saturday, May 23

Journal of the Formosan Medical AssociationMay 23

SGLT2 inhibitors and geriatric syndromes in older adults with type 2 diabetes: A real-world cohort study

Cohort study of 42,440 peopleSGLT2 inhibitors

Friday, May 1

American Journal of Respiratory and Critical Care MedicineMay 1

B51-21 BRASH Syndrome: Triggered by Sodium-glucose Cotransporter-2 (SGLT2) Inhibitors

Case reportMechanisms

American Journal of Respiratory and Critical Care MedicineMay 1

B52-20 A Broken Heart: Ozempic-Induced Takotsubo Cardiomyopathy

Case reportMechanisms

Sunday, April 26

Expert Opinion on Drug SafetyApr 26

Safety of SGLT2 inhibitors for patients with type 2 diabetes: where are we now?

ReviewSGLT2 inhibitors

Wednesday, April 1

Dermatologica SinicaApr 1

The expanding role of dermatologists in the era of glucagon-like peptide-1 receptor agonist therapies

ReviewGLP-1 receptor agonists

Friday, March 27

Medical SciencesMar 27

Safety Profile of SGLT-2 Inhibitors in Older Adults: A Systematic Review and Network Meta-Analysis

Meta-analysis of randomized trialsSGLT2 inhibitors

Friday, February 27

Monaldi Archives for Chest DiseaseFeb 27

Heart failure outcomes among reduced and preserved ejection fraction patients on sodium-glucose cotransporter-2 inhibitors with different dosing patterns of diuretics: a systematic review and meta-analysis

Meta-analysis of randomized trialsSGLT2 inhibitors

Tuesday, February 24

International Journal of Cardiology Cardiovascular Risk and PreventionFeb 24

Dose-dependent effects of SGLT2 inhibitors on circadian blood pressure in hypertensive patients with diabetes: A systematic review and Bayesian network meta-analysis

Meta-analysis of randomized trialsSGLT2 inhibitors